GoAI
Get started
Orchestra BioMed Holdings, Inc. logo

Orchestra BioMed Holdings, Inc.

OBIO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.36

−$0.07 · -1.29%

Aug 21, 4:00 PM ET

Pre-market

$5.0878

−$0.2722 · -5.08%

Aug 24, 7:15 AM ET

OBIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

73

Undervalued

Momentum

36

Weakening

Sentiment

56

Mixed

Risk resilience

48

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David Hochman
Listed since
Aug 4, 2020
Employees
86

Market position

Day range

Current $5.36

52-week range

Current $5.36

Open
$5.47
Previous close
$5.43
Volume
276.67K
0.89× average
Average volume
310.15K
Average daily volume
Market cap
320.96M USD
Beta
0.5
Market reference 1
50-day average
$4.1559
+28.97% above average
200-day average
$4.2199
+27.02% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
179.42M USD
P/E (TTM)
-5.41×
P/B (TTM)
11.63×
P/S (TTM)
10.04×
EV / EBITDA
-3.5×
Earnings yield
-26.60%
Free cash flow yield
-24.96%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.32%
Operating margin
-181.36%
Net margin
-184.60%
Return on equity
-83.15%
Return on assets
-45.88%
Return on invested capital
-52.40%

Financial health

Debt / equity
0.74×
Current ratio
6.45×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3481%1329%-823%-2976%Gross margin, FY2021: 125.45%Gross margin, FY2022: 90.89%Gross margin, FY2023: 93.26%Gross margin, FY2024: 92.27%Gross margin, FY2025: 99.43%Operating margin, FY2021: 2787.60%Operating margin, FY2022: -924.34%Operating margin, FY2023: -1866.16%Operating margin, FY2024: -2437.49%Operating margin, FY2025: -154.73%Net margin, FY2021: 2942.97%Net margin, FY2022: -951.26%Net margin, FY2023: -1779.71%Net margin, FY2024: -2313.27%Net margin, FY2025: -157.40%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 125.45%. Gross margin FY2022 90.89%. Gross margin FY2023 93.26%. Gross margin FY2024 92.27%. Gross margin FY2025 99.43%. Operating margin FY2021 2787.60%. Operating margin FY2022 -924.34%. Operating margin FY2023 -1866.16%. Operating margin FY2024 -2437.49%. Operating margin FY2025 -154.73%. Net margin FY2021 2942.97%. Net margin FY2022 -951.26%. Net margin FY2023 -1779.71%. Net margin FY2024 -2313.27%. Net margin FY2025 -157.40%.

Income trends

Revenue

33.48M USD+1169.22%

Operating income

−51.81M USD+19.43%

Net income

−52.7M USD+13.64%
Income trends across reported periods43.26M USD4.15M USD−34.97M USD−74.08M USDRevenue, FY2021: −782K USDRevenue, FY2022: 3.53M USDRevenue, FY2023: 2.76M USDRevenue, FY2024: 2.64M USDRevenue, FY2025: 33.48M USDOperating income, FY2021: −21.8M USDOperating income, FY2022: −32.66M USDOperating income, FY2023: −51.51M USDOperating income, FY2024: −64.3M USDOperating income, FY2025: −51.81M USDNet income, FY2021: −23.01M USDNet income, FY2022: −33.61M USDNet income, FY2023: −49.12M USDNet income, FY2024: −61.02M USDNet income, FY2025: −52.7M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 −782K USD. Revenue FY2022 3.53M USD. Revenue FY2023 2.76M USD. Revenue FY2024 2.64M USD. Revenue FY2025 33.48M USD. Operating income FY2021 −21.8M USD. Operating income FY2022 −32.66M USD. Operating income FY2023 −51.51M USD. Operating income FY2024 −64.3M USD. Operating income FY2025 −51.81M USD. Net income FY2021 −23.01M USD. Net income FY2022 −33.61M USD. Net income FY2023 −49.12M USD. Net income FY2024 −61.02M USD. Net income FY2025 −52.7M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue33.48M USD2.64M USD2.76M USD3.53M USD−782K USD
Cost of goods sold190K USD204K USD186K USD322K USD199K USD
Gross profit33.29M USD2.43M USD2.57M USD3.21M USD−981K USD
Research and development58.19M USD42.8M USD33.82M USD21.95M USD12.89M USD
Selling, general, and administrative26.91M USD23.93M USD20.26M USD13.92M USD7.93M USD
Operating expenses85.1M USD66.74M USD54.08M USD35.87M USD20.82M USD
Interest income—3.36M USD3.85M USD50K USD—
Interest expense1.15M USD———927K USD
Depreciation and amortization327K USD308K USD287K USD222K USD181K USD
Operating income−51.81M USD−64.3M USD−51.51M USD−32.66M USD−21.8M USD
Net income−52.7M USD−61.02M USD−49.12M USD−33.61M USD−23.01M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+15.23%
11 comparable reports
Latest EPS result
-0.38
Estimate -0.39 · Beat by 3.06%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.17-0.07-0.32-0.56Q1 '25BeatQ2 '25MetQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual -0.37, estimate -0.43, surprise +13.95%, Beat. Q2 2025, reported Apr 2, 2025: actual -0.43, estimate -0.43, surprise 0.00%, Met estimate. Q3 2025, reported Aug 12, 2025: actual -0.5, estimate -0.51, surprise +1.96%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.4, estimate -0.38, surprise -5.26%, Miss. Q1 2026, reported Mar 12, 2026: actual 0.12, estimate -0.38, surprise +131.58%, Beat. Q2 2026, reported May 12, 2026: actual -0.33, estimate -0.4, surprise +17.50%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.38, estimate -0.392, surprise +3.06%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.41, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates33.38M22.28M11.18M74.8KQ1 '25No estimateQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual 253K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 2, 2025: actual 253K USD, estimate 522.33K USD, surprise -51.56%, Miss. Q3 2025, reported Aug 12, 2025: actual 836K USD, estimate 778.83K USD, surprise +7.34%, Beat. Q4 2025, reported Nov 10, 2025: actual 861K USD, estimate 741.4K USD, surprise +16.13%, Beat. Q1 2026, reported Mar 12, 2026: actual 30.92M USD, estimate 931K USD, surprise +3220.84%, Beat. Q2 2026, reported May 12, 2026: actual 110K USD, estimate 918.71K USD, surprise -88.03%, Miss. Q3 2026, reported Aug 10, 2026: actual 88K USD, estimate 137.71K USD, surprise -36.10%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 133K USD, surprise —, Comparison unavailable.

OBIO news

globenewswire.com

Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference

NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through…

Read source
zacks.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago.

Read source
defenseworld.net

Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO

Affinity Asset Advisors LLC lessened its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) by 29.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange…

Read source
seekingalpha.com

Orchestra BioMed: Nearing The First Of Two Pivotal Readouts

Orchestra BioMed is approaching pivotal trial readouts for AVIM Therapy and Virtue SAB, both with strong success potential. OBIO operates as an innovation and clinical development platform for medical devices, relying on…

Read source
globenewswire.com

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through…

Read source
globenewswire.com

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through…

Read source

OBIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding OBIO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
5.85M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.44M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.03M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.98M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
1.18M
Weight
1.38%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.08M
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
888.61K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
735.92K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research OBIO

research.disclaimer